Day: April 9, 2026

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”), a North American critical minerals refining company, today announced the award of approximately C$7.8 million in construction contracts related to key infrastructure within its cobalt sulfate refinery in Ontario. The contracts establish defined construction scopes across key process areas, bringing additional portions of the refinery into active execution. Electra has awarded a contract valued at approximately C$6.8 million for structural, mechanical, and piping work associated with the refinery’s crystallizer circuit. The work is being executed by Pro Pipe Construction Ltd., a Northern Ontario-based subsidiary of Dalcon Construction, and includes fabrication and installation of piping systems...

Henrietta Treyz Joins as Contributor, Bringing Timely U.S. Policy and Economic Insight for Subscribers TORONTO, April 09, 2026 (GLOBE NEWSWIRE) — AGF Management Limited (AGF) today announced that Henrietta Treyz, Co-Founder and Director of Economic Policy at Veda Partners, will become a regular contributor as the firm launches Capitol Signals, a subscription-based newsletter. She will provide subscribers with weekly and ad hoc insights into how U.S. policy and political developments may impact global markets. Issues such as tariffs, fiscal stimulus, tax policy, the debt ceiling, and other key economic priorities in Washington, D.C will be covered. “Henrietta brings deep expertise in economic policy and a strong track record of helping investors understand the implications of political and legislative developments,” said Meaghan...

WASHINGTON, April 09, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that it will release financial results for the first quarter ended March 31, 2026 before the New York market opens on Thursday, April 30, 2026. A conference call will be held to discuss these financial results on Thursday, April 30, 2026, at 9:00 a.m. Eastern Time and will be hosted by senior management. The conference call will be simulcast live on the Internet and can be accessed by logging onto the Company’s investor relations website. A replay of the webcast will be available on the Company’s investor relations website for 90 days. About FTI ConsultingFTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories...

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France. The data to be presented build on earlier findings from the FIT-001 study reported at the 2025 European Society for Medical Oncology...

Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution capabilities as Plus advances REYOBIQ™ and CNS-focused pipeline HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the appointment of Eric J. Daniels, M.D., MBA, as Chief Development Officer, effective April 20, 2026. Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora...

MONTREAL, April 09, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) announces that Jean Martineau, who has served as President and CEO since 2007 will retire from the Corporation immediately following the June 2026 Annual Shareholder Meeting (“AGM”). As part of the Corporation’s succession planning, Daniel Misiano, who has served as the COO since 2024, will assume the role of President & CEO at that time. Mr. Martineau will stand for election to the Dynacor Board of Directors (“Board”) at the AGM. “Serving Dynacor for nearly two decades has been a joy and a privilege,” said Jean Martineau, President & CEO. “Since its start-up, we have scaled the business far beyond what we envisioned, growing operations ten-fold while maintaining a solid balance sheet and expanding...

DALLAS, April 09, 2026 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its first quarter 2026 financial results and second quarter 2026 outlook on Thursday, May 7, 2026, at 5:00 p.m. Eastern Time. On the same day, the Company also expects to issue an earnings news release after market close at approximately 4:15 p.m. Eastern Time. A live webcast of the call can be accessed through this webcast link, which also will be available on AMN Healthcare’s investor relations website. Interested parties may participate live via telephone by registering at this conference call link. Please follow the link and register with a valid e-mail address. A PIN will be provided to you with dial-in instructions. If you lose track of these details, please re-register at the conference call link...

Vancouver, BC, April 09, 2026 (GLOBE NEWSWIRE) — Big Bear Gold Corp. (TSXV: BEAR) (the “Company”) wishes to announce the results of its 2026 annual general meeting of shareholders (the “2026 AGM”) held on April 6, 2026.  Shareholders voted in favour of all matters brought before the meeting, including re-appointing Davidson & Company LLP, as the Company’s auditor and approving the Company’s new Omnibus Long-Term Incentive Plan (the “Omnibus Plan”).  In addition, Peter Laipnieks, Corey Klassen, Allen Schwabe and Matt Wayrynen were all re-elected as directors of the Company. The Omnibus Plan provides the Company with a variety of security-related mechanisms to attract, retain, and motivate qualified directors, employees, and consultants.  The Omnibus Plan replaced the Company’s prior stock option plan and includes (i) a 10% “rolling”...

Fully permitted for diamond drilling on niobium and rare earth targets at Seigneurie, Bardy and Blanchette Vancouver, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) — North American Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: KS82.F) (OTCQB: NIOMF) (“NIOB” or the Company) can launch maiden diamond drill programs at Bardy and Blanchette, after receiving an Authorization for Impact-Causing Exploration Work (ATI) for each project. Granted by Québec’s Ministère des Ressources naturelles et des Forêts (MRNF), the ATI authorizes the Company to proceed with diamond drilling targeting niobium and rare earth element mineralization at the 100% owned projects located approximately 45 km northwest of La Tuque in the Mauricie region. “We are now authorized to drill at three of our 100% owned projects in Québec: Bardy, Blanchette,...

JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions (DDIs) and liver toxicity. These results further support izicopan’s potential as a differentiated, best-in-class oral C5a receptor (C5aR) inhibitor. To build upon previous CYP interaction data for izicopan, which showed only marginal inhibition of CYP3A4 (IC₅₀ = 62 µM) in a time-dependent inhibition (TDI) IC₅₀ shift assay, InflaRx conducted a mechanistically informative Ki-based TDI (Ki/Kinact) study. While TDI shift assays serve as rapid screening tools to identify potential...